NEW YORK (GenomeWeb News) – German drug developer Sygnis Pharma has bought Amnestix, a spin-out from the Translational Genomics Research Institute, for €4 million ($6.3 million) in a cash and shares deal, Sygnis said today.
 
Amnestix, which was started by TGen researchers Dietrich Stephan and Matthew Huentelman in 2006 and was funded by the Brain Trust Accelerator Fund, is focused on developing therapeutics that can improve cognition and memory functions that are damaged by neurological diseases.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.